

AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

1. (Original) A method for treating a condition selected from the group consisting of Drug-Induced Dyskinesias, Tardive Dyskinesias, motor fluctuations, cognitive symptoms of Parkinson's Disease, Neuroleptic Malignant Syndrome, and negative symptoms of schizophrenia, said method comprising administering to a patient in need of said treatment, in an effective regimen and amount, a composition comprising an active ingredient which is a compound selected from the group consisting of: 7-chloro-4-(4-diethylamino-1-methylbutylamino)quinoline (chloroquine); 7-fluoro-4-(4-diethylamino-1-methylbutylamino)quinoline; 4-(4-diethylamino-1-methylbutylamino)quinoline; 7-hydroxy-4-(4-diethylamino-1-methylbutylamino)quinoline; 7-chloro-4-(4-diethylamino-1-butylamino)quinoline (desmethylchloroquine); 7-fluoro-4-(4-diethylamino-1-butylamino)quinoline; 4-(4-diethylamino-1-butylamino)quinoline; 7-hydroxy-4-(4-diethylamino-1-butylamino)quinoline; 7-chloro-4-(1-carboxy-4-diethylamino-1-butylamino)quinoline; 7-fluoro-4-(1-carboxy-4-diethylamino-1-butylamino)quinoline; 4-(1-carboxy-4-diethylamino-1-butylamino)quinoline; 7-hydroxy-4-(1-carboxy-4-diethylamino-1-butylamino)quinoline; 7-chloro-4-(1-carboxy-4-diethylamino-1-methylbutylamino)quinoline; 7-fluoro-4-(1-carboxy-4-diethylamino-1-methylbutylamino)quinoline; 4-(1-carboxy-4-diethylamino-1-methylbutylamino)quinoline; 7-hydroxy-4-(1-carboxy-4-diethylamino-1-methylbutylamino)quinoline; 7-chloro-4-(4-ethyl-(2-hydroxyethyl)-amino-1-methylbutylamino)quinoline (hydroxychloroquine); 7-fluoro-4-(4-ethyl-(2-hydroxyethyl)-amino-1-methylbutylamino)quinoline; 4-(4-ethyl-(2-

hydroxyethyl)-amino-1-methylbutylamino)quinoline 7-hydroxy-4-(4-ethyl-(2-hydroxyethyl)-amino-1-methylbutylamino)quinoline; hydroxychloroquine phosphate; 7-chloro-4-(4-ethyl-(2-hydroxyethyl)-amino-1-butylamino)quinoline (desmethylhydroxychloroquine); 7-fluoro-4-(4-ethyl-(2-hydroxyethyl)-amino-1-butylamino)quinoline; 4-(4-ethyl-(2-hydroxyethyl)-amino-1-butylamino)quinoline; 7-hydroxy-4-(4-ethyl-(2-hydroxyethyl)-amino-1-butylamino)quinoline; 7-chloro-4-(1-carboxy-4-ethyl-(2-hydroxyethyl)-amino-1-butylamino)quinoline; 7-fluoro-4-(1-carboxy-4-ethyl-(2-hydroxyethyl)-amino-1-butylamino)quinoline; 4-(1-carboxy-4-ethyl-(2-hydroxyethyl)-amino-1-butylamino)quinoline; 7-hydroxy-4-(1-carboxy-4-ethyl-(2-hydroxyethyl)-amino-1-butylamino)quinoline; 7-chloro-4-(1-carboxy-4-ethyl-(2-hydroxyethyl)-amino-1-methylbutylamino)quinoline; 7-fluoro-4-(1-carboxy-4-ethyl-(2-hydroxyethyl)-amino-1-methylbutylamino)quinoline; 4-(1-carboxy-4-ethyl-(2-hydroxyethyl)-amino-1-methylbutylamino)quinoline; 7-hydroxy-4-(1-carboxy-4-ethyl-(2-hydroxyethyl)-amino-1-methylbutylamino)quinoline; 8-[(4-aminopentyl)amino]-6-methoxydihydrochloride quinoline; 1-acetyl-1,2,3,4-tetrahydroquinoline; 8-[4-aminopentyl)amino]-6-methoxyquinoline dihydrochloride; 1-butyryl-1,2,3,4-tetrahydroquinoline; 3-chloro-4-(4-hydroxy-bis(2-methyl-1-pyrrolidinyl)-2,5-xylidino)quinoline, 4-[(4-diethylamino)-1-methylbutyl)amino]-6-methoxyquinoline; 3-fluoro-4-(4-hydroxy-bis(2-methyl-1-pyrrolidinyl)-2,5-xylidino)quinoline, 4-[(4-diethylamino)-1-methylbutyl)amino]-6-methoxyquinoline; 4-(4-hydroxy;-bis(2-methyl-1-pyrrolidinyl)-2,5-xylidino)quinoline, 4-[(4-diethylamino)-1-methylbutyl)amino]-6-methoxyquinoline; 3,4-dihydro-1-(2H)-quinolinecarboxyaldehyde; 1,1'-pentamethylenediquinoleinium diiodide; and 8-quinolinol sulfate, racemic mixtures, and enantiomers thereof, phosphate salts and other suitable pharmaceutical salts thereof, and mixtures thereof.

2. (Original) The method of claim 1 wherein said active ingredient is covalently linked or complexed or mixed with an adjuvant.
3. (Currently amended) The method of claim 2 wherein said adjuvant is a peripheral metabolism inhibitor that inhibits peripheral metabolism of said active ingredient wherein said peripheral metabolism inhibitor is an inhibitor of cytochrome P450 2D6 selected from the group consisting of amiodarone, celecoxib, chlorpheniramine, cimetidine, clomipramine, fluoxetine, levomepromazine, metoclopramide, mibefradil, moclobemide, paroxetine, quinidine, ranitidine, ritonavir, sertraline, and terbinafine; or a cytochrome P450 3A enzyme inhibitor selected from the group consisting of delaviridine, indinavir, nelfinavir, saquinavir, amiodarone, cimetidine, ciprofloxacin, clarithromycin, diethyl-dithiocarbamate, diltiazem, erythromycin, fluconazole, fluvoxamine, itraconazole, ketoconazole, mifepristone, nefazodone, norfloxacinem, and norfluoxetine; and racemic mixtures, enantiomers, suitable pharmaceutical salts of the foregoing, and mixtures of any of the foregoing.
4. Cancelled.
5. (Original) The method of claim 2 wherein said active ingredient and adjuvant are present in a time-release formula wherein said adjuvant is released about 1.5 to two hours prior to release of said active ingredient.
6. (Original) The method of claim 1 wherein said condition is a drug-induced dyskinesia.
7. (Original) The method of claim 6 wherein said drug-induced dyskinesia is selected from the group consisting of drug-induced Parkinson's Disease,

extrapyramidal disorders, akathisia, levodopa-induced dyskinesia, tardive dyskinesia, chorea and ballisms.

8. (Original) The method of claim 1 wherein said condition is motor fluctuations.
9. (Currently amended) The method of claim 1 wherein said ~~movement disorder~~ condition is selected from the group consisting of Drug-Induced Dyskinesias and Tardive Dyskinesias, ~~idiopathic Parkinson's Disease, multiple-symptom atrophy associated with Parkinson's Disease, Parkinson's Plus Syndrome, Atypical Parkinsonian Disorders, on-off syndrome associated with treatment with dopamine or a dopamine agonist, conditions characterized by nigrostriatal degeneration, vascular Parkinson's Disease, Huntington's Chorea, and Wilson's Disease.~~
10. (Original) The method of claim 1 wherein said condition is a negative symptom of schizophrenia.
11. (Original) The method of claim 10 wherein said negative symptom of schizophrenia is selected from the group consisting of apathy, loss of verbal fluency, affective flattening, lack of motivation, and depression.
12. (Original) The method of claim 1 wherein said condition is Neuroleptic Malignant Syndrome.
13. (Original) The method of claim 1 wherein said condition is a cognitive symptom of Parkinson's Disease selected from the group consisting of memory loss and loss of ability to multi-task.
- 14-36. Cancelled.